Lindsay Rein, MD, and Frederick Lansigan, MD, discuss current treatment standards for non-advanced systemic mastocytosis.
Back
Dissecting Key Updates in Non-Advanced Systemic Mastocytosis From ASH 2025
Lindsay Rein, MD, and Frederick Lansigan, MD, break down key data in non-advanced systemic mastocytosis from the 2025 ASH Annual Meeting.
Dissecting Key Updates in Non-Advanced Systemic Mastocytosis From ASH 2025
Episodes
All
All
Lindsay Rein, MD, and Frederick Lansigan, MD, delve into the frequency of KIT D816V mutations in non-advanced systemic mastocytosis.
Lindsay Rein, MD, and Frederick Lansigan, MD, compare the profiles of the investigational agent bezuclastinib and the approved agent avapritinib in non-advanced systemic mastocytosis.
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss data from the SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis.
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss additional findings from the SUMMIT trial from ASH 2025 for bezuclastinib in non-advanced systemic mastocytosis.
Lindsay Rein, MD, and Frederick Lansigan, MD, detail other key data from ASH 2025 for non-advanced systemic mastocytosis and ongoing research to watch in the space.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5